Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC-Sophia Children's Hospital, University Hospital Rotterdam, the Netherlands.
Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Center for CF and Airways Disease Research, Children's Healthcare of Atlanta, Atlanta, GA, USA.
J Cyst Fibros. 2020 Nov;19(6):902-909. doi: 10.1016/j.jcf.2020.01.010. Epub 2020 Feb 10.
Previously, we showed that abnormal levels of bioactive lipids in bronchoalveolar lavage fluid (BALF) from infants with cystic fibrosis (CF) correlated with early structural lung damage.
To extend these studies, BALF bioactive lipid measurement by mass spectrometry and chest computed tomography (CT, combined with the sensitive PRAGMA-CF scoring method) were performed longitudinally at 2-year intervals in a new cohort of CF children (n = 21, aged 1-5 yrs).
PRAGMA-CF, neutrophil elastase activity, and myeloperoxidase correlated with BALF lysolipids and isoprostanes, markers of oxidative stress, as well as prostaglandin E2 and combined ceramide precursors (Spearman's Rho > 0.5; P < 0.01 for all). Multiple protein agonists of inflammation and tissue remodeling, measured by Olink protein array, correlated positively (r = 0.44-0.79, p < 0.05) with PRAGMA-CF scores and bioactive lipid levels. Notably, levels of lysolipids, prostaglandin E2 and isoprostanes at first BALF predicted the evolution of PRAGMA-CF scores 2 years later. In wild-type differentiated primary bronchial epithelial cells, and in CFTR-inducible iCFBE cells, treatment with a lysolipid receptor agonist (VPC3114) enhanced shedding of pro-inflammatory and pro-fibrotic proteins.
Together, our findings suggest that bioactive lipids in BALF correlate with and possibly predict structural lung disease in CF children, which supports their use as biomarkers of disease progression and treatment efficacy. Furthermore, our data suggest a causative role of airway lysolipids and oxidative stress in the progression of early CF lung disease, unveiling potential therapeutic targets.
此前,我们发现囊性纤维化(CF)患儿支气管肺泡灌洗液(BALF)中生物活性脂质水平异常与早期结构性肺损伤相关。
为了扩展这些研究,我们对新的 CF 患儿队列(n=21,年龄 1-5 岁)进行了支气管肺泡灌洗液生物活性脂质的质谱测量和胸部计算机断层扫描(CT)(结合敏感的 PRAGMA-CF 评分方法),每两年进行一次纵向测量。
PRAGMA-CF、中性粒细胞弹性蛋白酶活性和髓过氧化物酶与 BALF 溶血磷脂和氧化应激标志物(异前列烷)以及前列腺素 E2 和联合神经酰胺前体呈正相关(Spearman's Rho>0.5;所有标志物 P<0.01)。通过 Olink 蛋白芯片测量的多种炎症和组织重塑的蛋白激动剂也呈正相关(r=0.44-0.79,p<0.05),与 PRAGMA-CF 评分和生物活性脂质水平相关。值得注意的是,第一次 BALF 中的溶血磷脂、前列腺素 E2 和异前列烷水平可预测 2 年后 PRAGMA-CF 评分的变化。在野生型分化的原代支气管上皮细胞和 CFTR 诱导的 iCFBE 细胞中,溶血磷脂受体激动剂(VPC3114)治疗可增强促炎和促纤维化蛋白的脱落。
总之,我们的发现表明,BALF 中的生物活性脂质与 CF 儿童的结构性肺疾病相关,并可能预测其疾病进展,支持将其用作疾病进展和治疗效果的生物标志物。此外,我们的数据表明气道溶血磷脂和氧化应激在 CF 早期肺疾病进展中起因果作用,揭示了潜在的治疗靶点。